Alli Sales Top 2 Million Starter Packs, Drive GSK’s OTC Sales
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's over-the-counter product sales posted a 24 percent increase to $854.6 million for the third quarter, driven in by U.S. sales of its alli weight loss drug, the firm said in an Oct. 24 earnings call
You may also be interested in...
GSK Counts On China, Product Innovation To Boost Consumer Product Sales
GlaxoSmithKline recently launched its Sensodyne toothpaste line in China, its first new product there in more than 10 years
GSK Counts On China, Product Innovation To Boost Consumer Product Sales
GlaxoSmithKline recently launched its Sensodyne toothpaste line in China, its first new product there in more than 10 years
GSK Counts On China, Product Innovation To Boost Consumer Product Sales
GlaxoSmithKline recently launched its Sensodyne toothpaste line in China, its first new product there in more than 10 years